SYF0a67b0f35f2c464ea44f72d01bea757fRegistry ID: 2023-505095-29-03|Not Yet RecruitingPhase 4
Loading search results
interventional
N/A
1 country
1
To determine whether intravenous iron (ferric carboxymaltose) would improve Quality of life and Exercise Capacity in patients with severe Aortic Stenosis and Iron Deficiency undergoing TAVI
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2, 2023
Actual (reported)Quality of life at 6 months (using the 23-item Kansas City Cardiomyopathy Questionnaire, KCCQ-23, as continuous variable)
Exercise capacity at 6 months (using 6-minute walk test, 6-MWT as continuous variable).
Cognitive function at 6 months (using the Mini Mental State Examination, MMSE as continuous variable).
NYHA classification at 6 months (as continuous variable).
Patient Global Assessment at 6 months (as continuous variable).
European Quality of Life-5 Dimensions Utility Index (EQ-5D-UI) and Visual Analog Scale (EQ-5D-VAS) at 6 months (as continuous variable).
Composite of cardiovascular mortality and heart failure hospitalizations at 6 months
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Rotterdam, 3015 GD, Netherlands
Dr RJ Nuis
First Submitted
October 2, 2023
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction
Contact the study team to confirm eligibility.